150267
Mental health and treatment services in juvenile correctional facilities
Tuesday, November 6, 2007: 12:30 PM
Dennis Waite, PhD
,
Department of Psychiatry & Neurobehavioral Sciences, University of Virginia, Charlottesville, VA
Twenty percent of children/adolescents in the general populations have mental health disorders. Youth in the juvenile justice system have up to 4 times that rate. This study documents the rates of designated mental health treatment needs in the juvenile correctional population of Virginia and discusses related issues. Blind-coded data were analyzed on 6,204 youth admitted to the Reception and Diagnostic Center from 1998-2003 representing 95-99% of admissions. An increase in documented history of psychotropic medication among committed youth was found, increasing from 24.3% in 1993 to 50.3% in 2003. Differences were found among youth by race and ethnicity in a number of areas. Black males and Hispanic males were least likely to have prior psychiatric hospitalizations. Documented suicide attempts were found in 16.4% of white females, 11.2% of Black females, 9.6% of white males; 2.7% of black males, and 3.6 of Hispanic males. Designated mental health treatment needs were reported in over 50% of youth overall. The role of the correctional facility in providing mental health treatment needs more consideration.
Learning Objectives: 1. Know the prevalence of mental health disorders, psychotropic medication use, and suicide attempts requiring medical attention in youth who are in the criminal justice system.
2. Articulate the issues concerning the historical role of the correctional facility as it pertains to providing mental health treatment.
3. Discuss 3 potential organizational models related to mental health care of juveniles.
Keywords: Adolescent Health, Criminal Justice
Presenting author's disclosure statement:Any relevant financial relationships? No Any institutionally-contracted trials related to this submission?
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|